3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
12
Stomach Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
HER2-positive Breast Cancer
3
Esophageal Neoplasms
3
Rectal Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Interventions
pembrolizumab
31
Paclitaxel
14
Carboplatin
12
Cisplatin
8
lenvatinib
7
Pemetrexed
5
olaparib
4
belzutifan
4
Oxaliplatin
4
Fluorouracil
4
Docetaxel
4
Capecitabine
4
patritumab deruxtecan
3
Leucovorin
3
Gemcitabine
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Saline Solution
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Dexamethasone
2
Cetuximab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Trastuzumab
×
30 days
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled